The transcription factor glioma-associated oncogene homolog 1 (GLI1) has a central function in gastrointestinal tract development and homeostasis. A non-synonymous single-nucleotide polymorphism (SNP) (rs2228226; Q1100E) in GLI1, which impairs GLI1 function in vitro, has been proposed as a risk factor for inflammatory bowel disease (IBD). In this study, we assessed the cumulative evidence for association of GLI1 with IBD. New genotype data for rs2228226 from New Zealand (907 controls, 990 IBD patients) and Belgian Caucasian case-control data sets (312 controls, 1214 IBD patients) were combined with data from the National Institute of Diabetes and Digestive and Kidney Diseases and three previously studied Caucasian case-control data sets. Meta-analysis of rs2228226 did not detect any association with ulcerative colitis (UC) (P ¼ 0.09, odds ratio (OR) ¼ 1.07, 95% confidence interval (CI) ¼ 0.92-1.24), Crohn's disease (CD) (P ¼ 0.29, OR ¼ 1.06, 95% CI ¼ 0.93-1.21) or overall IBD (P ¼ 0.15, OR ¼ 1.05, 95% CI ¼ 0.92-1.19). Our analyses of rs2228226 suggest that GLI1 is not a significant risk factor for IBD in Caucasians.
Introduction
Ulcerative colitis (UC) and Crohn's disease (CD) are polygenic inflammatory bowel diseases (IBDs), which are associated with considerable morbidity and are on the increase in Caucasian populations. 1 A recent study used a tagged single-nucleotide polymorphism (SNP) approach to characterize the variation in glioma-associated oncogene homolog 1 (GLI1) and tested for association with IBD in Scottish Caucasians. 2 Analysis of two tSNPs (rs2228224 and rs2228226) in this cohort demonstrated a significant association of GLI1 with both IBD and UC and a borderline association of GLI1 with CD, largely due to the non-synonymous rs22282260 (Q1100E), with the minor allele conferring susceptibility. The association of rs2228226 with UC, but not CD, was replicated in an IBD case-control data set of English Caucasians, but the minor allele frequency of this SNP did not differ significantly between Swedish IBD patients and controls. 2 This as yet unconfirmed IBD gene is located within the IBD2 linkage region 12q13.3.
3
GLI1 encodes a zinc-finger transcription factor acting on the Hedgehog signalling pathway, 4 which has a crucial function in the development and homeostasis of the gastrointestinal tract. This pathway may also be important for inflammatory responses as Hedgehog signalling is critical for the development of T lymphocytes, 5 CD4 þ T-cell activation, 6 myeloid cell maturation 7 and a direct transcriptional target of nuclear factor-kB. 8 The aim of our study was to genotype rs2228224 and rs2228226 in two additional Caucasian case-control data sets, combine this data with the Lees et al. 2 and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) CD data sets, and to conduct a meta-analysis to assess the cumulative evidence for association of GLI1 with IBD.
Results and discussion
A summary of the demographics and phenotypic data on each of the case-control data sets included in this study is provided in (Table 2) . A modest protective effect of rs2228226 with CD was detected in the NIDDK data set (P ¼ 0.032, OR ¼ 0.86, 95% CI ¼ 0.75-0.99 (Table 2 ). This data set contained exclusively CD cases with ileal involvement ( Of the four possible haplotype combinations of rs2228224 and rs2228226 only three (AC, GC, GG) occurred at an appreciable frequency in the New Zealand, Belgian and NIDDK data sets (Table 3) . These common haplotypes showed no evidence of association with CD, UC or IBD in the New Zealand and Belgian case-control data sets, whereas modest associations of the GG and AC haplotypes with CD were detected in the NIDDK data set (P AC haplotype ¼ 0. Demographic and phenotypic characteristics of each case-control data set have been described in detail elsewhere.
b Ethical approval to include the New Zealand and Belgian case-control data sets in this study was given by the Upper South Regional Ethics Committee (Canterbury, New Zealand) and the Ethics Committee of Leuven University (Leuven, Belgium), respectively. Approval to access the NIDDK CD (study accession: phs000130.v1.p1) and WTCCC CD data sets was granted by the National Centre for Biotechnology Information Genotypes and Phenotypes Database (NCBI dbGaP) Access Committee (request #3040-2), and the WTCCC Data Access Committee, respectively. a DNA was extracted from peripheral blood samples of the New Zealand and Belgian IBD patients and controls using sodium chloride 24 and guanidium isothiocyanate-chloroform. 25 Genotyping of rs2228224 and rs2228226 in the New Zealand and Belgian case-control data sets was performed using the pre-designed Taqman SNP genotyping assays C_3125146_10 and C_11293074_10 (Applied Biosystems, Foster City, CA, USA), and PCR-RFLP, respectively. The accuracy of the TaqMan and PCR-RFLP assays was confirmed by repeat analysis of 10% of samples and direct DNA sequencing of another 5% of samples. Concordance between original and repeat genotype calls was 100%. A web-based calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) was used to test for deviations from Hardy-Weinberg equilibrium and to conduct single marker association tests to assess whether the minor allele frequency (MAF) of rs2228224 and rs2228226 differed significantly between cases and controls. *Imputed genotypes for rs2228226 were generated from the NIDDK and WTCCC data sets using IMPUTE 26 and the most recent HapMap release (NCBI Build 36 dbSNP b126). A quality threshold of 0.90 was set for imputation of these data sets. 2 reported no association of rs2228226 with IBD in the smaller Swedish data set 2 and proposed that GLI1 was predominantly a risk factor for UC. This is despite an equally strong association of rs2228226 with CD in the Scottish data set and a subsequent meta-analysis that produced the same effect size (OR ¼ 1.2) regardless of whether controls were compared with UC patients only or all IBD patients. 2 To test for possible association with CD, we performed separate meta-analyses for CD and UC. In contrast to the combined analysis of Lees et al., 2 which showed association of rs2228226 with overall IBD (P ¼ 0.0002, OR ¼ 1.19, 95% CI ¼ 1.09-1.31) and UC (P ¼ 0.0008, OR ¼ 1.20, 95% CI ¼ 1.08-1.33), our UC-specific metaanalysis showed no significant association with UC (P ¼ 0.089, OR ¼ 1.07, 95% CI ¼ 0.92-1.24) (Figure 1a) . Similarly, our second meta-analysis that compared rs2228226 frequencies between CD patients and population-matched controls demonstrated that GLI1 was not significantly associated with CD (P ¼ 0.289, OR ¼ 1.06, 95% CI ¼ 0.93-1.21) (Figure 1b) . The WTCCC data set could not be included in this analysis because of a significant overlap with the Scottish and Cambridge case-control data sets (Lees C, personal communication). However, despite this overlap, single marker association testing of the WTCCC data set also did not support the initial finding of association of rs2228226 with CD in the Scottish cohort (P ¼ 0.37, OR ¼ 0.96, 95% CI ¼ 0.88-1.05) ( Table 2) . A final meta-analysis of all IBD cases vs all controls (excluding WTCCC) detected no evidence of universal association of GLI1 with IBD in Caucasians (P ¼ 0.145, OR ¼ 1.05, 95% CI ¼ 0.92-1.19) (Figure 1c) .
The Breslow-Day test revealed the existence of significant heterogeneity in the pattern of association of rs2228226 with IBD among the case-control data sets examined (P ¼ 0.01). Strong and consistent associations of NOD2, 9-11 ATG16L1, 10-13 IRGM 10,14-16 and IL23R [10] [11] [12] 17 with IBD has been previously reported in each data set, indicating that these data sets are homogeneous for confirmed IBD risk genes. To account for the heterogeneity observed for GLI1 meta-analysis was done using random effects model. To further investigate the possible causes of the heterogeneity, review of summary demographic and phenotypic data found no consistent differences between the populations that did and did not show evidence of association with rs2228226 ( Table 1) . The Belgian and NIDDK case-control data sets had fewer pure colonic CD cases and the New Zealand data set had more proctitis cases than the case-control data sets of Lees et al. 2 Conversely, a small number of indeterminate colitis patients were included in the Scotland data set (n ¼ 75 indeterminate colitis/884 IBD cases; 8.5%) and Cambridge cohort (n ¼ 83 indeterminate colitis/1737 IBD cases; 4.7%), whereas all other case-control data sets included only patients with a confirmed diagnosis of either CD or UC. However, whether any of these Figure 1 Meta-analyses of GLI1 SNP rs2228226 in six Caucasian populations. Meta-analyses of rs2228226 were performed in (a) ulcerative colitis (n ¼ 2729 cases and 3463 matched controls), (b) Crohn's disease (n ¼ 3255 cases and 4410 matched controls) and (c) inflammatory bowel disease (n ¼ 6142 cases and 4410 matched controls) by the Mantel-Haenszel method using a random effects model (Stata Statistics/Data Analysis Software, version 8, Stata Corporation, TX, USA). On the Forest plot, the 95% CI for the individual data sets are represented by horizontal lines, and the total number of study participants in each data set is proportional to the size of the square. The diamond represents the pooled OR with 95% CI delineated by the diamond's width. The combined UC data set, vs controls, had 98% power to detect an effect size of OR ¼ 1.19 (minor allele frequency ¼ 0.34, a ¼ 0.01), and the CD combined data set, vs controls, had 100% power to detect an effect size of OR ¼ 1.30 at the same level of significance. The combined data sets, IBD patients vs controls, had 100% power to detect an effect size of 1.23 (minor allele frequency ¼ 0.35, a ¼ 0.01).
differences contributed appreciably to the observed heterogeneity is unknown. Furthermore, the median age of diagnosis was similar across the case-control data sets, indicating that none of the data sets had a significantly higher proportion of early disease onset cases (Table 1) , which is often associated with a more severe disease phenotype and a stronger genetic predisposition. However, we cannot exclude the possibility that this heterogeneity is the result of geographic variation. The WTCCC identified 13 loci that show strong geographic variation within the United Kingdom even after the exclusion of individuals of non-European ancestry. 11 The cause of this variation is unknown but is likely to be the product of natural selection, possibly for resistance to infectious diseases. 11 It is plausible that GLI1 may be another locus that has undergone differential selection in different Caucasian populations.
The observations that GLI1 is downregulated in the inflamed intestinal mucosa of UC patients 18 and that mice with only one copy of Gli1 are more prone to developing severe DSS-induced colitis than their wildtype litter mates, 2 makes GLI1 a compelling candidate risk gene for IBD. The demonstration that rs2228226 results in a twofold reduction in the ability of GLI1 to activate transcription of target genes, and the association of this SNP with IBD in two European case-control data sets, further supports a role of GLI1 in IBD. 2 However, neither our well-powered meta-analysis nor any genomewide association study 13, [19] [20] [21] support the hypothesis that GLI1 universally alters susceptibility to IBD across Caucasian populations.
